ArticleSurgical endoscopy2026
Impact of preoperative depression severity and antidepressant medication use on perioperative outcomes and long-term weight loss following primary bariatric surgery.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression affects up to half of bariatric surgery candidates, yet the impact of depression severity and preoperative antidepressant pharmacotherapy use on surgical outcomes remains poorly characterized.
methodsThis was a retrospective cohort study of patients who underwent primary minimally invasive sleeve gastrectomy or Roux-en-Y gastric bypass at a single institution between January 2018 and June 2024. Depression severity was stratified using PHQ-9 scores obtained during standard preoperative psychological evaluation. Antidepressant use was classified by pharmacologic class and number of concurrent medications. The primary outcome was percent excess body weight loss (%EBWL) at 6, 12, 24, 36, 48, and 60 months postoperatively. Secondary outcomes included 30-day perioperative complications, readmissions, and emergency department visits.
resultsOf 930 patients identified, 128 (13.8%) carried a preoperative depression diagnosis. Patients with depression achieved significantly greater %EBWL at 6 months (46.9% vs. 43.1%, p = 0.026), 1 year (56.9% vs. 52.0%, p = 0.012), and 2 years (59.0% vs. 50.4%, p = 0.007) compared to those without depression, with no significant differences at later timepoints. Among patients with depression, those with none/minimal PHQ-9 severity had significantly greater %EBWL at 1 year compared to mild/moderate and moderately severe/severe groups (p = 0.031). No significant differences in 30-day perioperative complications were observed based on depression diagnosis or PHQ-9 severity category. However, patients with depression who were not taking antidepressants had significantly higher overall complication rates (11.5% vs. 0%, p = 0.002) and 30-day readmission rates (15.4% vs. 3.0%, p = 0.045) compared to those receiving antidepressant therapy.
conclusionsPreoperative depression is not a contraindication to bariatric surgery; patients with depression can achieve excellent short-term weight loss, particularly in the first two postoperative years. Optimizing preoperative depression treatment appears to reduce perioperative morbidity and may confer a protective effect on perioperative outcomes in this population.
Indexed as
Identifiers
42426388What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.